http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ#Head
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ#assertion
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ#provenance
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ#pubinfo
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ#assertion
http://purl.obolibrary.org/obo/DOID_8659
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_8659
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00577
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ#association
http://www.w3.org/2000/01/rdf-schema#label
adult patients 1 1 cold sores herpes labialis genital herpes treatment in immunocompetent patients initial or recurrent episode suppression in immunocompetent or hiv infected patients reduction of transmission herpes zoster pediatric patients 1 2 cold sores herpes labialis limitations of use 1 3 the efficacy and safety of valacyclovir hydrochloride tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in hiv infected patients cold sores herpes labialis valacyclovir hydrochloride tablets are indicated for treatment of cold sores herpes labialis the efficacy of valacyclovir hydrochloride tablets initiated after the development of clinical signs of a cold sore e g papule vesicle or ulcer has not been established genital herpes initial episode valacyclovir hydrochloride tablets are indicated for treatment of the initial episode of genital herpes in immunocompetent adults the efficacy of treatment with valacyclovir hydrochloride tablets when initiated more than 72 hours after the onset of signs and symptoms has not been established valacyclovir hydrochloride tablets are indicated for treatment of recurrent episodes of genital herpes in immunocompetent adults the efficacy of treatment with valacyclovir hydrochloride tablets when initiated more than 24 hours after the onset of signs and symptoms has not been established valacyclovir hydrochloride tablets are indicated for chronic suppressive therapy of recurrent episodes of genital herpes in immunocompetent and in hiv infected adults the efficacy and safety of valacyclovir hydrochloride tablets for the suppression of genital herpes beyond 1 year in immunocompetent patients and beyond 6 months in hiv infected patients have not been established valacyclovir hydrochloride tablets are indicated for the reduction of transmission of genital herpes in immunocompetent adults the efficacy of valacyclovir hydrochloride tablets for the reduction of transmission of genital herpes beyond 8 months in discordant couples has not been established the efficacy of valacyclovir hydrochloride tablets for the reduction of transmission of genital herpes in individuals with multiple partners and non heterosexual couples has not been established safer sex practices should be used with suppressive therapy see current centers for disease control and prevention cdc sexually transmitted diseases treatment guidelines herpes zoster valacyclovir hydrochloride tablets are indicated for the treatment of herpes zoster shingles in immunocompetent adults the efficacy of valacyclovir hydrochloride tablets when initiated more than 72 hours after the onset of rash and the efficacy and safety of valacyclovir hydrochloride tablets for treatment of disseminated herpes zoster have not been established cold sores herpes labialis valacyclovir hydrochloride tablets are indicated for the treatment of cold sores herpes labialis in pediatric patients 12 years of age the efficacy of valacyclovir hydrochloride tablets initiated after the development of clinical signs of a cold sore e g papule vesicle or ulcer has not been established labeling describing use of valacyclovir hydrochloride tablets in pediatric patients with chickenpox ages 2 to 18 years is approved for glaxosmithkline s valtrex r caplets however due to glaxosmithkline s marketing exclusivity rights a description of that pediatric use is not approved for this valacyclovir hydrochloride tablet product the efficacy and safety of valacyclovir hydrochloride tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in hiv infected patients with a cd4 cell count 1 cells mm 3 patients 12 years of age with cold sores herpes labialis patients 18 years of age with genital herpes patients 18 years of age with herpes zoster neonates and infants as suppressive therapy following neonatal herpes simplex virus hsv infection labeling describing use of valacyclovir hydrochloride tablets in pediatric patients with chickenpox ages of 2 to 18 years is approved for glaxosmithkline s valtrex r
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00577
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ#provenance
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ#pubinfo
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ#sig
http://purl.org/nanopub/x/hasSignature
CZ8sAThyK4dKUkSRR1jTueb1JOcL2uXxxaZTLkVZcTKL4A7BPxkaKXdaKF4e3ByvO3Hhx5zly4k3Lv4mXbmymYY84VV6oGtbKH7PcsswGSdtK+iud3i6sIhYDnGtS4xeFJnFiXoWxgX8y7H5uoK6cCR4Iv3ZjP9X2G6OxPEsRbU=
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ
http://purl.org/dc/terms/created
2021-06-30T08:43:47.685+02:00
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAUPA0VzQXmWo5Bk0WcKyXOAMu7vn4X32DqefrYB291AQ
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs